Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
43.56
-1.77 (-3.90%)
At close: Apr 28, 2026, 4:00 PM EDT
44.29
+0.73 (1.68%)
After-hours: Apr 28, 2026, 7:57 PM EDT
Structure Therapeutics Employees
Structure Therapeutics had 220 employees as of December 31, 2025. The number of employees increased by 57 or 34.97% compared to the previous year.
Employees
220
Change (1Y)
57
Growth (1Y)
34.97%
Revenue / Employee
n/a
Profits / Employee
-$641,827
Market Cap
3.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220 | 57 | 34.97% |
| Dec 31, 2024 | 163 | 70 | 75.27% |
| Dec 31, 2023 | 93 | 25 | 36.76% |
| Dec 31, 2022 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Denali Therapeutics | 503 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Alumis | 224 |
| Edgewise Therapeutics | 146 |
| Erasca | 103 |
GPCR News
- 1 day ago - Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions - GlobeNewsWire
- 14 days ago - Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - GlobeNewsWire
- 27 days ago - What's Going On With Structure Therapeutics Stock On Wednesday? - Benzinga
- 6 weeks ago - Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate? - Barrons
- 6 weeks ago - Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16% - Benzinga
- 6 weeks ago - Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - GlobeNewsWire
- 2 months ago - Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 3 months ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters